---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-004232"
form_type: "8-K"
ticker: "SEER"
cik: "0001726445"
company_name: "Seer, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:44:46.570032+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Seer Q4 2021 rev $3.1M, FY rev $6.6M; guides FY2022 rev $14-16M

## Summary
- Q4 revenue $3.1M (up from $336K YoY); net loss $19.7M vs $12.9M.
- Full-year 2021 revenue $6.6M vs $656K; net loss $71.2M vs $32.8M.
- Gross margin 47% in Q4, 52% for full year; cash+investments $493.3M.
- Shipped 17 instruments through year-end 2021; broad commercial release of Proteograph commenced.
- 2022 revenue guidance $14-16M; expects to increase investments in commercial, ops, and R&D.

## SEC filing metadata
- accession: 0001628280-22-004232
- form_type: 8-K
- ticker: SEER
- cik: 0001726445
- company_name: Seer, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726445/000162828022004232/0001628280-22-004232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726445/000162828022004232/seer-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-004232
- JSON: https://secwatch.observer/filing/0001628280-22-004232.json
- Plain text: https://secwatch.observer/filing/0001628280-22-004232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.